Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Aptinyx

Explore full profile

Biopharmaceutical company discovering and developing innovative therapies for challenging disorders of the brain and nervous system

Evanston, United StatesFounded 2015Biotech & Life Sciences
Valuation $6.5M Market cap · 2024
Revenue $1.0M Latest reported FY

About Aptinyx

Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing transformative therapies for challenging disorders of the brain and nervous system. The company leverages its proprietary NMDA receptor modulator discovery platform to create novel therapeutic solutions for a range of central nervous system (CNS) disorders. Aptinyx's current pipeline includes multiple candidates in late-stage clinical development targeting conditions such as chronic pain and post-traumatic stress disorder (PTSD).

Aptinyx operates in the biopharmaceutical market, primarily serving patients suffering from CNS disorders. The business model is centered around the research and development of new drug candidates, which are then brought through clinical trials to demonstrate efficacy and safety. Revenue is generated through partnerships, licensing agreements, and eventually, the commercialization of successful therapies.

Source: Dealroom company data

At a glance

Status
Listed
Founded
2015
Headquarters
Evanston, United States
Listing
IPO 2018
Sector
Biotech & Life Sciences

Investors

14 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • National Institutes of Health

Series A12 investors entered at this stage

  • New Leaf Venture Partners
  • Latterell Venture Partners
  • Longitude Capital
  • Osage University Partners
  • Frazier Healthcare Partners
  • Beecken Petty O'Keefe & Company
  • Goudy Park Capital
  • Adams Street Partners
  • Bain Capital Life Sciences
  • Rock Springs Capital
  • Agent Capital
  • PFM Health Sciences

Series B and later1 investor entered at this stage

  • K2 HealthVentures
Team profiled 7 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Aptinyx on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Aptinyx on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.